pH-Responsive Apalutamide-Loaded ZIF‑8 Nanoparticles for Zinc-Enhanced Dual Cytotoxicity in Prostate Cancer
Apalutamide (APA) is a recently FDA-approved androgen receptor inhibitor for the treatment of nonmetastatic castration-resistant prostate cancer. Herein, we report a pH-responsive, dual-acting nanocarrier system based on zeolitic imidazolate framework-8 (ZIF-8) to enhance the therapeutic efficacy of APA. APA was succes...